Author: Pishesha, Novalia; Harmand, Thibault J; Rothlauf, Paul W; Praest, Patrique; Alexander, Ryan K; van den Doel, Renate; Liebeskind, Mariel J; Vakaki, Maria A; McCaul, Nicholas; Wijne, Charlotte; Verhaar, Elisha; Pinney, William; Heston, Hailey; Bloyet, Louis-Marie; Pontelli, Marjorie Cornejo; Ilagan, Ma Xenia G; Jan Lebbink, Robert; Buchser, William J; Wiertz, Emmanuel J H J; Whelan, Sean P J; Ploegh, Hidde L
Title: A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants Cord-id: ozhxfs9c Document date: 2021_1_1
ID: ozhxfs9c
Snippet: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 100 million infections and millions of deaths. Effective vaccines remain the best hope of curtailing SARS-CoV-2 transmission, morbidity, and mortality. The vaccines in current use require cold storage and sophisticated manufacturing capacity, which complicates their distribution, especially in less developed countries. We report the development of a candidate SARS-CoV-2 vaccine that is purely
Document: The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 100 million infections and millions of deaths. Effective vaccines remain the best hope of curtailing SARS-CoV-2 transmission, morbidity, and mortality. The vaccines in current use require cold storage and sophisticated manufacturing capacity, which complicates their distribution, especially in less developed countries. We report the development of a candidate SARS-CoV-2 vaccine that is purely protein based and directly targets antigen-presenting cells. It consists of the SARS-CoV-2 Spike receptor-binding domain (SpikeRBD) fused to an alpaca-derived nanobody that recognizes class II major histocompatibility complex antigens (VHHMHCII). This vaccine elicits robust humoral and cellular immunity against SARS-CoV-2 and its variants. Both young and aged mice immunized with two doses of VHHMHCII-SpikeRBD elicit high-titer binding and neutralizing antibodies. Immunization also induces strong cellular immunity, including a robust CD8 T cell response. VHHMHCII-SpikeRBD is stable for at least 7 d at room temperature and can be lyophilized without loss of efficacy.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date